We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

218 hedge funds and large institutions have $3.68B invested in Neurocrine Biosciences in 2017 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 72 increasing their positions, 80 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more capital invested

Capital invested by funds: $3.27B → $3.68B (+$417M)

3% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 37

0.51% more ownership

Funds ownership: 97.13% → 97.64% (+0.51%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

3% less funds holding

Funds holding: 225 → 218 (-7)

10% less repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 80

39% less call options, than puts

Call options by funds: $12.3M | Put options by funds: $20.3M

Holders
218
Holders Change
-7
Holders Change %
-3.11%
% of All Funds
5.43%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.15%
New
38
Increased
72
Reduced
80
Closed
37
Calls
$12.3M
Puts
$20.3M
Net Calls
-$8.01M
Net Calls Change
-$6.53M

Top Buyers

1
BlackRock
BlackRock
New York
+$214M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$87.4M
3
JHIU
Janus Henderson Investors US
Colorado
+$85.8M
4
Goldman Sachs
Goldman Sachs
New York
+$42.7M
5
Citadel Advisors
Citadel Advisors
Florida
+$30.7M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$80M
2
O
OrbiMed
New York
-$72.3M
3
Millennium Management
Millennium Management
New York
-$51.7M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$39.4M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$26.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
MWNA
26
Marshall Wace North America
New York
$34.9M +$34.8M +811,880 New
Norges Bank
27
Norges Bank
Norway
$34.4M -$4.43M -103,360 -12%
Macquarie Group
28
Macquarie Group
Australia
$33.6M +$6.16M +143,825 +23%
Geode Capital Management
29
Geode Capital Management
Massachusetts
$29.3M +$1.83M +42,752 +7%
First Trust Advisors
30
First Trust Advisors
Illinois
$28.4M -$982K -22,928 -3%
Jennison Associates
31
Jennison Associates
New York
$28.2M +$12M +280,963 +76%
RG
32
Redmile Group
California
$26.9M +$26.7M +622,345 New
UBS AM
33
UBS AM
Illinois
$25.8M +$734K +17,124 +3%
TCM
34
TimesSquare Capital Management
New York
$25.1M +$2.08M +48,573 +9%
GPP
35
Great Point Partners
Connecticut
$24.2M -$8.14M -190,000 -25%
O
36
OppenheimerFunds
New York
$21.4M -$17.4M -406,768 -45%
Northern Trust
37
Northern Trust
Illinois
$20.4M +$621K +14,493 +3%
TCM
38
Tekla Capital Management
Massachusetts
$19.3M +$2.32M +54,205 +14%
O
39
OrbiMed
New York
$19.1M -$72.3M -1,687,433 -79%
Neuberger Berman Group
40
Neuberger Berman Group
New York
$18.7M +$4.82M +112,500 +35%
Bank of America
41
Bank of America
North Carolina
$18.2M +$7.64M +178,326 +74%
RSCM
42
Rock Springs Capital Management
Maryland
$17.8M – – –
Charles Schwab
43
Charles Schwab
California
$15M +$1.17M +27,245 +9%
CS
44
Credit Suisse
Switzerland
$14.2M +$3.89M +90,741 +38%
AG
45
Artal Group
Luxembourg
$14.1M +$7.5M +175,000 +117%
EA
46
Emerald Advisers
Pennsylvania
$13.2M -$376K -8,777 -3%
CAM
47
Cormorant Asset Management
Massachusetts
$13M -$2.53M -59,000 -16%
GTC
48
Ghost Tree Capital
New York
$13M +$12.9M +300,000 New
Wells Fargo
49
Wells Fargo
California
$12.9M +$7.51M +175,292 +144%
TCIM
50
TIAA CREF Investment Management
New York
$11.8M +$1.7M +39,717 +17%
1
2
3 4 5

NBIX Hedge Fund Activity: Q1 2017 in Review

218 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q1 2017, worth a combined $3.68B — up 13% from $3.27B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new NBIX positions and 37 closed out — a net gain of 1 holder — while 72 added to existing stakes and 80 trimmed.

The largest buyer was BlackRock, adding an estimated $214M. The largest seller was T. Rowe Price Associates, cutting an estimated $80M.

  • 218 institutional investors held Neurocrine Biosciences (NBIX) as of Q1 2017, down from 225 in Q4 2016.
  • Funds reported $3.68B of Neurocrine Biosciences stock for Q1 2017, up 13% quarter-over-quarter.
  • 38 funds opened new Neurocrine Biosciences positions in Q1 2017 and 37 closed out, a net change of +1 holder.
  • The largest Neurocrine Biosciences buyer in Q1 2017 was BlackRock, an estimated $214M added.
  • The largest Neurocrine Biosciences seller in Q1 2017 was T. Rowe Price Associates, an estimated $80M sold.

Based on aggregated 13F filings for Q1 2017.